Page 23 - Expanded Access Program News Today

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta VariantOpaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, adding

Investor interest is pushing psychedelics-based therapy mainstream and it’s now time to figure out the tricky regulatory issues that have held these therapies back, as the leading developer moves towards seeking approval in 2023.

In addition to the Company’s eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular...

Read the latest Ivermectin headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on Ivermectin...

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update ATUs in France in Europe in H1 2022 Successful refinancing in Q1 2021 secures mid-2023 runway Multiple regulatory and clinical milestones expected in Q4 2021 Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cen...

Investigational magnetic device shrinks glioblastoma in first-in-world human test Houston Methodist Neurological Institute researchers from the department of neurosurgery shrunk a deadly glioblastoma tumor by more than a third using a helmet generating a noninvasive oscillating magnetic field that the patient wore on his head while administering the therapy in his own home. The 53-year-old patient died from an unrelated injury about a month into the treatment, but during that short time, 31% o...

-in -class SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohns dis...

– June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC). The resulting cost savings include an approximate two thirds reduction in our global workforce. Orphazyme remains committed to pursuing regulatory approval in Europe and assessing a path forward for arimoclomol in the U.S. following r...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Orphazyme announces restructuring to focus resources on supporting a path forward for ... ORPHAZYME A/SJune 28, 2021 GMT Orphazyme A/S - Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type...

Share this article Share this article DUBLIN, June 15, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft ® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns). P...